Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by Pandoraon Dec 18, 2021 10:41pm
76 Views
Post# 34244239

RE:RE:RE:Wednesday Trading

RE:RE:RE:Wednesday TradingIn attempting to read this post are we to assume it was done on a cell phone with fat fingers? That's the most common reason given for something like this. I have no idea what it is supposed to say.


CASHEAGLE wrote:

AGN

   is going to be $100

m once it hits NAsdaq...that s is just the valuation and 
chris 
Moreai has done this before..He works with promoy=ters and gets results..He too AGN from $.02 namd tarded 1B agn shares on covid fever  he qalmsot nlew $12M in phqse i on covid with zero to show.

But he isno wonto a cough del that is going to be $1..it might repets his oast sucess in d=getting    f=da approvals..he i  horsento bet on..buy aat $ and sell at 

4.50 om=n his last sucess

 

 

 

 


































4.04



<< Previous
Bullboard Posts
Next >>